Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar 1;23(131):79-91.
doi: 10.1183/09059180.00008913.

Therapeutic options targeting angiogenesis in nonsmall cell lung cancer

Lucio Crinò  1 , Giulio Metro
Affiliations
Review

Therapeutic options targeting angiogenesis in nonsmall cell lung cancer

Lucio Crinò et al. Eur Respir Rev. .

Abstract

There is a major unmet medical need for effective and well-tolerated treatment options for patients with advanced nonsmall cell lung cancer (NSCLC), in both first-line and relapsed/refractory settings. Experimental evidence has validated signalling pathways that regulate tumour angiogenesis, including the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) pathways, as valid anti-cancer drug targets. However, to date, bevacizumab (an anti-VEGF monoclonal antibody) is the only antiangiogenic agent to be approved for the treatment of NSCLC. Many other agents, including antibodies, small-molecule tyrosine kinase inhibitors and vascular disrupting agents, have been assessed in phase III trials but have generally failed to demonstrate clinically meaningful benefits. This lack of success probably reflects the redundancy of proangiogenic pathways and the molecular and clinical heterogeneity of NSCLC. In this review we summarise recently completed and ongoing randomised clinical trials of emerging antiangiogenic agents in patients with NSCLC. We highlight recent promising data with agents that simultaneously inhibit multiple proangiogenic pathways, including the PDGF and FGF pathways, as well as the VEGF pathway. Finally, we discuss the outlook for antiangiogenic agents in NSCLC, emphasising the need for clinically validated prognostic and predictive biomarkers to identify patients most likely to respond to therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1.
Figure 1.
Molecular pathways underlying angiogenesis. A: Tumour cells produce vascular endothelial growth factor (VEGF)-A and other angiogenic factors, such as basic fibroblast growth factor (bFGF), angiopoietins, interleukin-8, placental growth factor and VEGF-C. These stimulate resident endothelial cells to proliferate and migrate. B: An additional source of angiogenic factors is the stroma. This is a heterogeneous compartment, comprising fibroblastic, inflammatory and immune cells. Recent studies indicate that tumour-associated fibroblasts produce chemokines, such as stromal cell-derived factor (SDF)-1, which may recruit bone-marrow-derived angiogenic cells (BMC). VEGF-A or placental growth factor may also recruit BMC. Tumour cells may also release stromal cell-recruitment factors, such as platelet-derived growth factor (PDGF)-A, PDGF-C or transforming growth factor (TGF)-β. A well-established function of tumour-associated fibroblasts is the production of growth/survival factor for tumour cells, such as epidermal growth factor (EGF) receptor ligands, hepatocyte growth factor and heregulin. C: Endothelial cells produce PDGF-B, which promotes recruitment of pericytes in the microvasculature after activation of PDGF receptor-β. HGF: hepatocyte growth factor. Reproduced from [10] with permission.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. American Cancer Society. Non-small cell lung cancer survival rates by stage. www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-c... Date last updated: July 12, 2013. Date last accessed: October 2013.
    1. Peters S, Adjei AA, Gridelli C, et al. . Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23: Suppl. 7, vii56 vii64. - PubMed
    1. Sculier JP, Moro-Sibilot D. First- and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J 2009; 33: 915–930. - PubMed
    1. Oxnard GR, Arcila ME, Chmielecki J, et al. . New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011; 17: 5530–5537. - PMC - PubMed
    1. Shepherd FA, Dancey J, Ramlau R, et al. . Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095–2103. - PubMed

Publication types

MeSH terms